NEW YORK – Syndax Pharmaceuticals said this week that the US Food and Drug Administration designated revumenib as a breakthrough therapy for patients with relapsed or refractory acute leukemia bearing a KMT2A rearrangement. In Phase I studies, 27 percent of patients with KMT2A-rearranged leukemia achieved a complete remission. The company is evaluating revumenib in mutlple Phase I and II trials.
Seagen Canada said this week that Tukysa (tucatinib) will be covered through BC Cancer, the Provincial Health Services Authority in British Columbia. Tukysa plus Genentech's Herceptin (trastuzumab) and capecitabine is indicated for the treatment of patients with locally advanced, unresectable, or metastatic HER2-positive breast cancer, including patients with brain metastases, and who has received prior HER2-targeted therapy.
In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared in Precision Oncology News.